Global Markets Latest Research Reports: Central Nervous System Drugs Global Market Report 2018

Showing posts with label Central Nervous System Drugs Global Market Report 2018. Show all posts

Sep 24, 2018

Regenerative Therapies For CNS Diseases In The Global Central Nervous System Drugs Market (Companies Included: Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc., Novartis AG, Shire Plc., UCB S.A., Eli Lilly And Company, Sanofi S.A., Daiichi Sankyo Company, Limited)

The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities. Top selling neurological drugs in 2016 include Copaxone, Lyrica, and Tecfidera.

The global central nervous system drugs market has been growing in the past years with a CAGR of almost 5.2%. TBRC’s latest report show the historic and future trends in the market for each year with sourced reasons to support the growth claims.

The report also shows the global central nervous system drugs market to grow at a higher CAGR by 2021 as compared to 2017, along with geographies best suited for investments with highest return rate.

Download sample report at:

https://www.thebusinessresearchcompany.com/sample.aspx?id=279&type=smp

Regenerative therapies for the treatment of central nervous system diseases is one of the emerging trends in the global central nervous system drugs market. CNS diseases such as Alzheimer’s, Parkinson’s disease, spinal cord injury and optic neuropathies are complex disorders and cannot be completely cured by current therapeutic strategies, hence facilitating the need for regenerative therapies. Regenerative therapies are medications that replace, engineer or regrow damaged cells to treat a particular disease. These therapies help in the healing process by regenerating human cells, tissues, and organs. Major regenerative therapies include transplantation by embryonic stem cells, usage of matrix such as fibrin, collagen, and hyaluronic acid.

Request for discount: https://www.thebusinessresearchcompany.com/sample.aspx?id=279&type=discount

Companies included in the report are Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson,

Pfizer Inc., Novartis AG, Shire Plc., UCB S.A., Eli Lilly And Company, Sanofi S.A., and Daiichi Sankyo Company, Limited.

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Jul 4, 2018

Global Central Nervous System Drugs Market Is Expected To Grow To $90 Billion By 2021 According To TBRC’s Latest Report

The substantial growth of the market from $72 billion in 2017 to around $90 billion by 2021 is due to the steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions. The geriatric population and rise in diseases such as Parkinson’s, Alzheimer’s and other mental disorders is also likely to continue to drive the market for central nervous system drugs.

In the report, the global central nervous system drugs market is divided into five segments. Other CNS drugs occupy the major share, accounting for more than two-fifth of the market. Anaesthetics is the second largest segment, occupying one-fifth of the market share and the remaining two-fifth of the market share is occupied by the other three segments namely, analgesics, anti-parkinson drugs and anti-epileptics.

Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=258&type=smp

The USA was the largest country in the central nervous system drugs market in 2017, accounting for more than one-fourth of the market share. This can be attributed to high drug prices and increased healthcare spending in the USA compared to other countries. Germany and China followed the USA as the next largest countries in the market.

The central nervous system drugs market is fragmented with a number of large and small organizations. The top five competitors in the market made up around two-fifth of the total market in 2017. Biogen Inc. was the largest competitor of the market, followed by F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc. and Novartis AG. Biogen Inc. was founded in 1978 and is headquartered in Massachusetts, USA. It is involved in discovering, developing, and selling medical products used to treat neurological disorders such as multiple sclerosis, and inflammatory diseases such as rheumatoid arthritis. Biogen Idec has offices in Australia, the Brazil, Japan, India, and China.

About The Business Research Company.

Contact Information.